Quercetin
In clinical developmentAlso known as 3'-HYDROXYKAEMPFEROL, Sophoretin, poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one+3 more
3'-HYDROXYKAEMPFEROL, Sophoretin, poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one, 3,3',4',5,7-pentahydroxyflavone, 3,5,7,3',4'-Pentahydroxyflavone, FLAVONE, 3,3',4',5,7-PENTAHYDROXY-.
Recent clinical, regulatory, research and industry developments relating to this drug.
Pilot Study of Quercetin Patients With Dyskeratosis Congenita/Telomere Biology Disorders
Improving Physical Ability and Cellular Senescence Elimination in HIV
ALSENLITE: An Open-Label Pilot Study of Senolytics for Alzheimer's Disease
SENolytics to Improve Osteoporosis Therapy: a Randomised Controlled Clinical Trial The SENIOR Trial
The Differential Effect of Senolytics on SASP Cytokine Secretion and Regulation of EMT by CAFs.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- International journal of molecular sciences4
- Molecules (Basel, Switzerland)3
- Frontiers in immunology2
- Oxidative medicine and cellular longevity2
- Aging1
- Aging cell1
- Akkol EK1
- Amevor FK1
- Aschner M1
- Behrens MD1
- Belotserkovskaya EV1
- Bernier PL1
- Berrill M1
- Bogdanova DA1
- Abdul Wali Khan University1
- Albert Einstein College of Medicine1
- Barshop Institute for Longevity and Aging Studies1
- Burnett School of Biomedical Sciences1
- Central University of Haryana1
- College of Science and Engineering1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 3 of the same disease areas as Quercetin in the shared literature.
Studied across 4 of the same disease areas as Quercetin in the shared literature.
Studied across 4 of the same disease areas as Quercetin in the shared literature.
Studied across 4 of the same disease areas as Quercetin in the shared literature.
Studied across 3 of the same disease areas as Quercetin in the shared literature.
Studied across 2 of the same disease areas as Quercetin in the shared literature.
Studied across the same disease area as Quercetin in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials